Who is sponsoring NCT03736850?

NCT03736850 is sponsored by CStone Pharmaceuticals.

What drugs are being tested in NCT03736850?

Interventions in NCT03736850: CS3006.

What condition does NCT03736850 study?

NCT03736850 studies Locally Advanced or Metastatic Solid Tumors.

Is NCT03736850 still recruiting?

NCT03736850 is currently completed. Last updated 12 January 2021.

Last reviewed 2021-01-12 · How we verify

NCT03736850

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Completed Phase 1 Last updated 12 January 2021

What this trial tests

Phase 1 trial testing CS3006 in Locally Advanced or Metastatic Solid Tumors in 17 participants. Completed in 15 May 2020.

Timeline

19 October 2018

Primary endpoint
15 May 2020

15 May 2020

Quick facts

Lead sponsor	CStone Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	19 October 2018
Primary completion	15 May 2020
Estimated completion	15 May 2020
Sites	1 location across China

Drugs / interventions tested

CS3006 — full drug profile →

Conditions studied

Locally Advanced or Metastatic Solid Tumors — all drugs for Locally Advanced or Metastatic Solid Tumors →

Sponsor

CStone Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Locally Advanced or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open label, sequential-cohort, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose (MTD）, if any, Recommended Phase II Doses (RP2Ds) and regimen of CS3006. The study is composed of two parts: Part 1 for dose escalation and Part 2 for dose expansion.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.
Yuan J, Dong X, Yap J, Hu J. · · 2020 · cited 388× · PMID 32807225 · DOI 10.1186/s13045-020-00949-4
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R, Galvin R, Watson AL, Largaespada DA, et al · · 2021 · cited 19× · PMID 33721151 · DOI 10.1007/s11912-021-01032-y

Verify or expand the search:

Other trials of CS3006

Trials testing the same drug.

NCT03516123 — A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors · Phase 1 · completed

Other recruiting trials for Locally Advanced or Metastatic Solid Tumors

Currently open trials in the same condition.

NCT07202364 — A Study of YL202 in Patients With Advanced Solid Tumors · Phase 2 · recruiting
NCT06418061 — Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07461181 — A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced · Phase 1, PHASE2 · active not recruiting
NCT06545331 — Study of XB010 in Subjects With Solid Tumors · Phase 1 · recruiting
NCT06328439 — A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other CStone Pharmaceuticals trials

Trials by the same sponsor.

NCT05381753 — Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World · completed
NCT05279300 — A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas · Phase 1 · recruiting
NCT04421352 — Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients · Phase 1 · completed
NCT04233060 — A Study of CS3005 in Advanced Solid Tumors · Phase 1 · completed
NCT04162301 — A Study of CS3002 in Subjects With Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03736850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CStone Pharmaceuticals
Last refreshed: 12 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03736850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing